BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36591807)

  • 1. Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
    Sýkorová A; Procházka V; Móciková H; Janíková A; Pytlík R; Belada D; Benešová K; Klener P; Ďuraš J; Smolej L; Campr V; Blahovcová P; Trněný M
    Neoplasma; 2022 Dec; 69(6):1466-1473. PubMed ID: 36591807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burkitt Lymphoma International Prognostic Index.
    Olszewski AJ; Jakobsen LH; Collins GP; Cwynarski K; Bachanova V; Blum KA; Boughan KM; Bower M; Dalla Pria A; Danilov A; David KA; Diefenbach C; Ellin F; Epperla N; Farooq U; Feldman TA; Gerrie AS; Jagadeesh D; Kamdar M; Karmali R; Kassam S; Kenkre VP; Khan N; Kim SH; Klein AK; Lossos IS; Lunning MA; Martin P; Martinez-Calle N; Montoto S; Naik S; Palmisiano N; Peace D; Phillips EH; Phillips TJ; Portell CA; Reddy N; Santarsieri A; Sarraf Yazdy M; Smeland KB; Smith SE; Smith SD; Sundaram S; Zayac AS; Zhang XY; Zhu C; Cheah CY; El-Galaly TC; Evens AM
    J Clin Oncol; 2021 Apr; 39(10):1129-1138. PubMed ID: 33502927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics and Outcomes of AIDS-Related Burkitt Lymphoma in China: A Retrospective Single-Center Study.
    Liu R; Zhao H; Xiao G; Tao Y; Tang X; Feng L; Liao B; Liu B; Guan J; Li L; Chen Z; He H; You H
    Technol Cancer Res Treat; 2024; 23():15330338231214236. PubMed ID: 38179657
    [No Abstract]   [Full Text] [Related]  

  • 4. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of clinical and prognostic factors for primary gastric diffuse large B-cell lymphoma: Single-center experience.
    Bardakci M; Esmer DD; Hafizoglu E; Karaman K; Kuzu OF; Karakas H; Gungorer B; Uncu D
    J Cancer Res Ther; 2023; 19(3):778-782. PubMed ID: 37470610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
    Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
    Advani RH; Chen H; Habermann TM; Morrison VA; Weller EA; Fisher RI; Peterson BA; Gascoyne RD; Horning SJ; ; ;
    Br J Haematol; 2010 Oct; 151(2):143-51. PubMed ID: 20735398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis].
    Man J; Chen L; Zhai XW; Ma YY; Wang HS; Qian XW; Feng JY; Zhao J; Cao P; Lu FJ
    Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):156-161. PubMed ID: 32074729
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimal dosage of rituximab for children with Burkitt lymphoma.
    Huang S; Jin L; Yang J; Zhang M; Zhang Y; Peng Y; Duan Y; Zheng H
    Ann Hematol; 2024 Mar; 103(3):893-903. PubMed ID: 38091052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 12. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors.
    Miralles P; Berenguer J; Ribera JM; Rubio R; Mahillo B; Téllez MJ; Lacruz J; Valencia E; Santos J; Rodríguez-Arrondo F; Pintado V;
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):167-73. PubMed ID: 17117144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Strategies and Prognostic Factors of Primary Gastric Diffuse Large B Cell Lymphoma: A Retrospective Multicenter Study of 272 Cases from the China Lymphoma Patient Registry.
    Yang H; Wu M; Shen Y; Lei T; Mi L; Leng X; Ping L; Xie Y; Song Y; Cen X; Zhu J
    Int J Med Sci; 2019; 16(7):1023-1031. PubMed ID: 31341416
    [No Abstract]   [Full Text] [Related]  

  • 14. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
    Evens AM; Danilov A; Jagadeesh D; Sperling A; Kim SH; Vaca R; Wei C; Rector D; Sundaram S; Reddy N; Lin Y; Farooq U; D'Angelo C; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Yazdy M; Rabinovich E; Varma G; Karmali R; Mian A; Savani M; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein AK; Blum KA; Boughan KM; Smith SE; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Ramdial J; Maliske SM; Epperla N; Venugopal P; Feldman TA; Smith SD; Stadnik A; David KA; Naik S; Lossos IS; Lunning MA; Caimi P; Kamdar M; Palmisiano N; Bachanova V; Portell CA; Phillips T; Olszewski AJ; Alderuccio JP
    Blood; 2021 Jan; 137(3):374-386. PubMed ID: 32663292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical features and prognosis of children with Burkitt's lymphoma: an analysis of 62 cases].
    Wang YC; DU WC; Yin CY; Gong X; Li YF
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 May; 24(5):561-565. PubMed ID: 35644197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
    Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
    Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
    Chen H; Zhong Q; Zhou Y; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Zhou L; Shi Y
    BMC Cancer; 2022 May; 22(1):583. PubMed ID: 35624433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
    McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
    Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
    Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
    Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
    Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.